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Abstract

*Correspondence to:

Alzheimer’s disease (AD), a fatal progressive neurodegenerative disorder, has no cure to date. One of the
causes of AD is the accumulation of amyloid-beta 42 (Aβ42) plaques, which result in the onset of neurodegeneration. It is not known how these plaques trigger the onset of neurodegeneration. There are several
animal models developed to (i) study etiology of disease, (ii) look for genetic modifiers, and (iii) identify
chemical inhibitors that can block neurodegeneration and help to find cure for this disease. An insect
model of Drosophila melanogaster has also provided new insights into the disease. Here we will discuss the
utility of the Drosophila eye model to study Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD) represents a complex class of debilitating brain diseases that mostly affects people aged 65 and
older. AD is characterized by progressive loss of neurons in
the hippocampus and cortex, which results in the shrinkage
of brain. Basically, the brain cells required to process, store
and retrieve information are killed, which is characteristic
of a neurodegenerative process (Singh, 2012). It results in
decline in cognitive and behavioral functions like memory,
thinking and language skills (O’Brien and Wong, 2010). AD,
a common form of dementia, is a progressive neurodegenerative disorder, which killed half a million people in 2010. AD
is aptly called as the silver tsunami of the 21st first century. It
is the sixth leading cause of death in US. It is estimated that
by 2050, the number of people with AD may nearly triple,
from 5 million to as many as 16 million, barring the development of medical breakthroughs to prevent, slow or stop
the disease (Xu, 2016). To date, there is no effective cure.
AD neuropathology is a proteinopathy, which is an outcome of misfolded proteins. AD is associated with two types
of abnormal protein deposition in the human brain: (1)
neurofibrillary tangles (NFTs) containing hyper-phosphorylated forms of a microtubule associated protein Tau, and (2)
accumulation of the plaques of amyloid-beta (Aβ42) peptide
due to aggregation prone amyloidogenic domains (Hardy,

2009; Aguzzi and O’Connor, 2010; Fernandez-Funez et al.,
2013; Selkoe and Hardy, 2016).

Generation of Amyloid-beta Plaques in AD
One of the hallmarks of AD is the accumulation of amyloid
plaques in the brain. In the healthy brain these plaques are
not present. The focus of this review is on the accumulation
of Aβ42 polypeptides formed by the improper cleavage of
a transmembrane amyloid precursor protein (APP) in the
brain (Figure 1) (Hardy, 2009; Aguzzi and O’Connor, 2010;
O’Brien and Wong, 2010; Fernandez-Funez et al., 2013).
Mutations in the gene encoding for APP have been linked
to the familial form of AD. APP is proteolytically processed
in the extracellular and intracellular domains by α and
then γ-secretase enzymes, which leads to the generation of
a forty amino acid long polypeptide (Aβ40), which causes
age-dependent learning defects but no neurodegeneration.
However, the differential cleavage of APP by the activities
of β- and γ-secretase enzymes lead to generation of forty
two amino acid long polypeptide, hence Aβ42 (Figure 1)
(Hardy, 2009; Aguzzi and O’Connor, 2010; O’Brien and
Wong, 2010; Fernandez-Funez et al., 2013; Selkoe and Hardy, 2016). These extra two amino acids cause the amyloid
Aβ42 polypeptide to become hydrophobic, resulting in formation of the amyloid plaques. Increased level of the more
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[Downloaded free from http://www.nrronline.org on Thursday, June 16, 2016, IP: 131.238.108.120]

Sarkar A, et al. / Neural Regeneration Research. 2016;11(5):693-697.

Phospholipid bilayer
Nonamyloidogenic
pathway

Amyloidogenic
pathway

APP

Aβ40

Aβ42
Alpha (α) secretase
Beta (β) secretase
Gamma (γ) secretase

A

B

HEALTHY NEURON

DYING NEURON
Amyloid monomer

Aβ42
Amyloid
plaque

C

D

Amyloid fibril

Aβ42

ADULT EYE

toxic form of human Aβ42 polypeptide is responsible for
the neuropathology seen in AD. These plaques disrupt normal cellular processes through oxidative stress and aberrant
signaling, resulting in the loss of synaptic activity and death
of neurons.
Even though many gene mutations responsible for AD
have been identified, the detailed genetic signaling mechanism(s) responsible for this neurodegeneration and progression of AD remain indefinable. A great deal of efforts are
channeled towards discerning the underlying mechanisms
that induce Aβ42 metabolism and the pathways (e.g., apoptosis and autophagy) that trigger neuronal cell death. The
rationale is to identify the molecular genetic mechanism
of generation of amyloid (Aβ42) accumulation, which will
allow (a) development of biomarkers for early detection of
AD, and (b) development of strategies to prevent accumulation of amyloid plaques, thereby leading to identification
of drug targets for AD. These insights can lead to a cure or
better therapeutic strategies for this disease.
694

Figure 1 Schematic presentation
of generation of amyloid-beta 42
(Aβ42) plaques.
Aβ42 are generated by improper
cleavage of amyloid precursor proteins (APP). APP a transmembrane
protein, is cleaved by alpha (α)-sectretase and gamma (γ)-secretase to
generate forty amino-acid (Aβ40)
long polypeptide. However, when
APP is cleaved by beta (β)-secretase
and gamma (γ)-secretase it generates forty two amino-acid (Aβ42)
long polypeptide. Aβ42 polypeptide
oligomerize to form a plaque.

Figure 2 Drosophila melanogaster
(fruit fly) eye model exhibits
neurodegeneration due to
accumulation of amyloid-beta 42
(Aβ42) plaques.
Accumulation of Aβ42 plaques
in (A) healthy neuron triggers
(B) death of a meuron. (C, D)
Misexpression of human Aβ42 in
healthy photoreceptor neurons of
Drosophila eye using transgenic
approach causes a (C) wild-type
adult compound eye to change into
a (D) highly reduced adult eye due
to induction of neuronal cell death
(Tare et al., 2011).

ADULT EYE

Animal Models for AD
Clinical trials largely aimed at removing these Aβ42 plaques
have not yet been efficient. Aβ42 mediated neurodegeneration is a dominant gain-of-function phenotype. Misexpression of human Aβ42 polypeptides trigger neurodegeneration in traditional mammalian models like the Mouse (Mus
musculus) as well as in the genetically tractable alternative
models like zebrafish (Danio rerio), roundworm (Caenorhabditis elegans), and the fruit fly (Drosophila melanogaster)
(Iijima and Iijima-Ando, 2008; Moloney et al., 2010; Harvey et al., 2011; Singh and Irvine, 2012). It has been seen
that the primary structures of the Aβ peptide in rats and
mice differ from their human counterpart at three amino
acid residues. Furthermore, the complete Aβ-peptide profile produced by the processing of APP in these rodents exhibits major differences in comparison to that of humans.
In guinea pigs, the rabbit Aβ peptide sequence is identical
to human but does not present AD pathology spontaneously. Therefore, alternative animal models for AD have been
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developed to understand the mechanism(s) of regulation
of human Aβ42 protein accumulation, and identification of
the signaling pathways (e.g., cell death) involved to generate
insights into the etiology of the disease (Bier, 2005; Singh
and Irvine, 2012; Moloney et al., 2010; Pandey and Nichols,
2011; Tare et al., 2011).
Using an insect Drosophila melanogaster (a.k.a. fruit fly),
to model human disease is beneficial for many reasons (Bier,
2005). Most importantly, their entire genome is sequenced,
and is highly conserved with humans and is significantly less
redundant (Lenz et al., 2013). Furthermore, they are smaller
in size and thus can be stored efficiently, are cost effective,
and can produce two generations in a month (Bier, 2005;
Singh and Irvine, 2012; Lenz et al., 2013). It makes Drosophila an ideal model for studying age related progressive
diseases like AD. Several models of AD have been developed
in Drosophila. These include transgenic flies misexpressing
human Aβ42, human Aβ40, human APP, BACE, β-secretase
and Drosophila Psn, FAD (Cauchi and van den Heuvel, 2006;
Cao et al., 2008; Iijima and Iijima-Ando, 2008; Tare et al.,
2011; Fernandez-Funez et al., 2013). These flies display several aspects of clinical AD neuropathology and symptoms
including the generation of amyloid aggregates, external
morphological abnormalities, dramatic neuroanatomical
changes and defects in motor reflex behavior and memory.
As a proof of concept, treatment with a γ-secretase inhibitor
was shown to suppress these phenotypes. Drosophila has also
proved informative as a model of other neurodegenerative
diseases like Parkinson’s disease, Huntington’s disease, fronto-temporal lobar degeneration (FTLD), and amyotrophic
lateral sclerosis (Bier, 2005; Pandey and Nichols, 2011; Singh
and Irvine, 2012; Fernandez-Funez et al., 2013).

Drosophila Eye as Disease Model System
Drosophila has a fully functional nervous system with a
structural design that separates specialized functions such
as vision, olfaction, learning and memory. The Drosophila
eye develops from a simple monolayer epithelium called the
eye-antennal imaginal disc which grows during larval stages to form a highly organized compound eye comprised of
photoreceptor cells, cone cells, and pigment cells (Ready et
al., 1976; Kumar, 2011; Singh et al., 2012; Kumar, 2013; Tare
et al., 2013). The precise structure of Drosophila eye makes
it very sensitive to genetic disruptions/manipulations and it
can be easily screened using a stereo microscope for phenotypes generated in the eye field. Thus, Drosophila eye allows
quick screening of large sample size. The Drosophila model
has a repertoire of tools that make it indispensable, including the ability to express foreign genes along spatio-temporal
axes that can mimic several important neurodegenerative
disorders in the compound eye (Bier, 2005; Singh and Irvine,
2012). Adding to this, the eye is not essential for the viability
or fertility of the fly. Therefore, the Drosophila eye is an ideal
organ system to assay the effect of neurodegeneration. Furthermore, the genes involved in eye development are structurally and functionally similar between insects and humans.
The main advantage of the Drosophila eye is the ability to

directly visualize the cellular and developmental defects induced by neurodegeneration causing agents.
We have utilized Drosophila eye to model Aβ42 mediated
neurodegeneration. Using Gal4/UAS transgenic systems
(Brand and Perrimon, 1993), we misexpressed human Aβ42
in the differentiating photoreceptor neurons of the developing eye (Tare et al., 2011; Moran et al., 2013; Steffensmeier et
al., 2013; Cutler et al., 2015). It resulted in progressive neurodegenerative phenotype; Cutler et al., 2015 in the Drosophila eye, which is similar to AD like neuropathology (Figure
2). However, Drosophila model has some challenges too. In
comparison to the vertebrates, Drosophila has less complex
and adaptive immune system. Furthermore, effects of drugs
on the organism might differ strongly (Prussing et al., 2013).

Drosophila Model for Genetic Screens
Drosophila model has been extensively used to screen (i) for
genetic modifiers responsible for onset and manifestation of
disease and (ii) chemical libraries to look for therapeutic targets to find cure for the disease. Drosophila model with the
repertoire of genetic tools allows several different approaches like a forward genetic screens, which involve a random
mutagenesis via chemicals or X-ray radiation and then to
identify the genes responsible for that phenotype, or reverse
genetic screen where you mutate a gene and then look for
the phenotype caused by loss-of-function of that gene (Bier,
2005; Singh and Irvine, 2012). Forward genetic screens are
decidedly useful as evidenced by the Nobel prize awarded to
C. Nüsslein-Volhard, E. Wieschaus and E.B. Lewis in 1995
for their work in identifying genes involved in early fruit
fly development (Nusslein-Volhard and Wieschaus, 1980;
St Johnston, 2002; Lenz et al., 2013). However, mapping of
mutations using a classical genetic approach can be time
consuming. The advent of new genetic tools, like single nucleotide polymorphisms (SNPs), has alleviated some of this
problem in forward genetic screens (Lenz et al., 2013). Despite this, few strictly forward genetic screens have been undertaken in an AD background using a Drosophila model. In
reverse genetic screens, a known gene is disrupted, typically
utilizing the Gal4/UAS system (Brand and Perrimon, 1993)
to misexpress a gene or silence a gene using RNA interference (RNAi) (Lenz et al., 2013).
Modifier (also known as enhancer or suppressor) screens
are highly valuable because they combine the advantages
of both forward and reverse genetics and carried out using
easily assayable phenotypes (Lenz et al., 2013; Prussing et al.,
2013). In AD, the Aβ42 neurodegenerative phenotype and
the rough eye phenotype are easily assayable phenotypes
(Tare et al., 2011). A Drosophila eye model was established
where Aβ42 is misexpressed in the developing fly eye results
in highly reduced neurodegenerative eye (Cao et al., 2008; Iijima and Iijima-Ando, 2008; Tare et al., 2011). We employed
this model for a small scale modifier screen to look for the
genetic modifiers which can either enhance/suppress the AD
eye phenotype by increasing levels of highly conserved signaling pathways (one at a time) (Tare et al., 2011; Moran et
al., 2013). Using this screen, we have identified the homeotic
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gene teashirt (tsh), highly conserved apical basal polarity
marker Crumbs (Crb) (Steffensmeier et al., 2013) as modifiers of Aβ42 mediated neurodegeneration, making these
genes as possible target for AD therapies.
The similar logic was utilized for several high throughput
screens (HTS) as well as smaller screens to identify genetic
modifiers of AD. Though many genetic screens for modifiers of Tau induced neurodegeneration have been carried
out, few large-scale screens have investigated modifiers of
the Aβ42 neurodegenerative phenotype (Lenz et al., 2013;
Prussing et al., 2013). Several other earlier genetic screens
to identify modifiers of the Aβ42 phenotype have resulted
in a list of potential downstream genetic targets (Cao et al.,
2008). Tan et al. used a screen to identify loss of function
mutations that either suppressed or enhanced the Aβ42 neurodegenerative phenotype (Tan et al., 2008). Using a IInd
and IIIrd chromosome deficiency kit they identified a deficiency that uncovers Toll (Tl) suppresses the Aβ42 mediated
neurodegeneration. Binding of the Toll extracellular domain
initiates a signaling cascade that eventually leads to activation the NFκB signaling, a pathway which plays a role in innate immunity and inflammatory responses. Tan et al. (2008)
identified this inflammatory signaling as playing a key role
in promoting neurodegenerative processes.
Ultimately, the goal of these types of genetic screens is to
identify a particular protein or signaling pathway member,
which is involved in AD mediated neuropathology that can
finally be targeted with a chemical compound (Pandey and
Nichols, 2011). Identification of such a chemical compound is
typically accomplished by in vitro HTS of a chemical library.
Once a compound is identified, it is optimized for human
usage through a series of tests in animal models. This process
can be inefficient when utilizing traditional in vitro cell cultures or biochemical assays. Furthermore, the paradigm in
therapeutic treatments has shifted from “one disease-one target” to an understanding that many diseases result from a variety of factors and interactions. Based on these two problems
with traditional methods in drug development, Drosophila
has emerged as a valuable model (Pandey and Nichols, 2011).
It has already been noted that Drosophila as a model is
space, time and resource efficient (Lenz et al., 2013). In
terms of drug development, flies present an advantageous
supplement or alternative to traditional methods because
they allow chemical compounds to be tested in vivo in a
whole organism as opposed to an isolated culture (Pandey
and Nichols, 2011). Though considerations regarding the
discrepancies between flies and humans in pharmacokinetics, pharmacodynamics and the toxicity of particular drug
administered in Drosophila are necessary, overall the model
has emerged as highly useful in secondary post screening
validation. Even though other disease systems have utilized
Drosophila as primary screening models, there are currently no studies which have utilized Drosophila as a primary
screening model for novel drug discovery in AD (Pandey
and Nichols, 2011).
Drug administration typically takes the form of solid
media to which drugs are added and larvae are allowed to
696

grow on. Though Drosophila are useful for HTS, the amount
of chemicals screened is significantly lower, typically 500 to
1,000 small molecules per month, than traditional cell culture assays, which can screen as many as 10,000 small molecules per month. Despite this, screens utilizing flies typically
result in a higher proportion of hits with therapeutic value.
In AD models like Drosophila, traditional HTS are frequently
utilized first to take advantage of their efficiency and identified small molecules are then tested in flies (Pandey and
Nichols, 2011).
One such screen to utilize Drosophila as secondary post
screening validation identified a particular small molecule
that inhibited Aβ peptide aggregation. Using a traditional
HTS based on Aβ42-GFP fusion they identified an inhibitor
of Aβ aggregation. The most effective inhibitor, D737, was
administered to transgenic flies with Aβ42 misexpressed in
neural tissues. They found that not only did the compound
reduce the toxicity of Aβ42 oligomers, but that it also increased the lifespan of the Aβ42 transgenic flies and their
locomotive activity (McKoy et al., 2012).
A recent study examined the neuroprotective effect of
a flavonoid derivative, 2-(4′ Benzloxyphenyl)-3-hydroxychromen-4-one, on the rough eye phenotype of transgenic
Aβ42 flies (Singh et al., 2014). The compound was identified
using an in silico docking approach, then administered to
transgenic Aβ42 flies to test in vivo. Approximately 70% of
Aβ42 transgenic flies showed a rescued eye phenotype and
there was a significant reduction in plaques in Aβ42 transgenic larvae (Singh et al., 2014). While this type of post
screening validation is certainly valuable, other disease models, including epilepsy and Fragile X syndrome (Stilwell et
al., 2006), have taken advantage of Drosophila as a primary
screening tool.

Conclusion
Here the vast contribution and potential of the Drosophila
eye as a model for understanding the cellular and molecular
mechanisms of neurodegeneration was explored. The eye
model can be exploited for initial screening of the genetic
modifiers or chemical inhibitor targets, as well as candidate
validation. The Drosophila eye as a validation tool in drug
discovery has gained momentum, which allows identification of compounds that would likely be effective in mammalian models and humans. Genetic and pharmacological
screens in the fly eye will serve as a strong screening tool for
therapeutic approaches in the future.
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